Developing vaccines to protect against SARS-CoV-2 variants
Official title: Mucosal subunit vaccines against SARS CoV-2
Funded at Ohio State University · NIH-11106030 · Data updated 2026-11-12
This study is testing a new type of vaccine that aims to provide long-lasting protection against COVID-19 by boosting your immune response, and it's designed for anyone interested in better ways to fight off the virus and its variants.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Ohio State University NIH-funded |
| Lab location | 1 site (Columbus, UNITED STATES) |
| Project start | June 5, 2024 |
| Project end | April 30, 2029 |
| Funding year | 2025 |
| Award (this year) | $745,036 |
| NIH project number | 5R01AI181270-02 |
| Project ID | NIH-11106030 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are adults aged 21 and older who are at risk of COVID-19 infection.
✕Less likely to help
Patients who are not at risk for COVID-19 or those who have already been vaccinated with effective vaccines may not benefit from this research.
What this research studies
This research focuses on creating mucosal vaccines that can effectively combat SARS-CoV-2 variants by generating long-lasting immunity. It aims to enhance both cell-mediated and humoral immune responses, which are crucial for protection against respiratory infections. The study explores the use of a novel adjuvant, Bordetella Colonization Factor A (BcfA), which promotes a more effective immune response compared to traditional adjuvants like alum. By targeting the immune system's T follicular helper cells and memory B cells, the research seeks to improve the durability of vaccine-induced protection.
Why it matters
Potential benefit: If successful, this research could lead to more effective vaccines that provide long-lasting protection against COVID-19 variants.
How similar studies have gone: Other research has shown promise in developing vaccines with novel adjuvants, indicating potential for success with this approach.
Where this research is happening
-
Ohio State University
Columbus, United States Active
Researchers
- Principal investigator: Dubey, Purnima — Ohio State University
- Study coordinator: Dubey, Purnima
Related research
Other NIH-funded projects on the same topics.
-
How COVID-19 infection and genes may influence memory and dementia risk
This study looks at how getting COVID-19 and a person’s genes together affect the chance of developing memory problems and Alzheimer’s disease later in life.
-
Understanding flu and COVID-19 vaccine responses in people and in the lab
Researchers at Stanford explore how flu and COVID-19 vaccines work in people and in lab tests to improve protection for adults.
-
Oral small molecule inhibitors to block SARS-CoV-2 RNA replication
A Stanford-led project tests a pill that could stop SARS-CoV-2 and related viruses from copying their RNA inside infected cells.
-
Outpatient antiviral cocktails to fight SARS-CoV-2 and future RNA viruses
Researchers at Stanford are developing outpatient antiviral cocktails that could be used easily outside the hospital to treat COVID-19 and future RNA virus infections.
-
Inhibitors for SARS-CoV-2 Proteases to Block Viral Replication
A patient-facing program aims to discover and optimize small molecules that block key SARS-CoV-2 enzymes, potentially reducing viral replication.
-
How different COVID-19 vaccines shape immune responses
This project compares immune reactions after mRNA and adenoviral COVID-19 vaccines to learn how long protection lasts and why some people get breakthrough infections or side effects.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.